News ‘Trojan horse’ cancer drug shows promise in multiple tumour ... A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
News Seattle Genetics and Astellas gain Breakthrough Designation ... The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
Partner Content Partner Content Exclusive Speaker Interview from Seattle Genetics for SMi’s ... Interview from Seattle Genetics
News Seattle, Takeda aim for first line Adcetris use Seattle CEO hopes Adcetris will be standard of care.
News Seattle Genetics halts trials of latest ADC after safety war... Monitoring committee concerned about high death rates.
News Seattle Genetics leukaemia trial on hold after 4 deaths FDA concerned over potential liver toxicity.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.